Metastatic rhabdomyosarcoma: Evidence of the impact of radiotherapy on survival. A retrospective single‐center experience

The prognosis for patients with metastatic rhabdomyosarcoma (RMS) remains largely unsatisfactory despite the adoption of intensive multimodal therapy. To assess the role of different treatments adopted over the years, we retrospectively analyzed a cohort of patients <21 years old with metastatic RMS, treated from 1990 to 2020 at a referral center for pediatric sarcomas.

[1]  K. McHugh,et al.  The Impact of Radiotherapy in Children and Adolescents with Metastatic Rhabdomyosarcoma. , 2021, International journal of radiation oncology, biology, physics.

[2]  A. Ferrari,et al.  Integrating Irinotecan in standard chemotherapy: a novel dose density combination for High-Risk pediatric Sarcomas , 2020 .

[3]  A. Ferrari,et al.  VIVA (vinorelbine, ifosfamide, vincristine, actinomycin‐D): A new regimen in the armamentarium of systemic therapy for high‐risk rhabdomyosarcoma , 2020, Pediatric blood & cancer.

[4]  H. Heslop,et al.  Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma , 2020, Nature Communications.

[5]  A. Ferrari,et al.  A home run for rhabdomyosarcoma after 30 years: What now? , 2019, Tumori.

[6]  A. Ferrari,et al.  Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial. , 2019, The Lancet. Oncology.

[7]  James R. Anderson,et al.  The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma , 2018, Cancer.

[8]  James R. Anderson,et al.  Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  M. Stevens,et al.  Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial. , 2018, The Lancet. Oncology.

[10]  M. Chintagumpala,et al.  Local therapy to distant metastatic sites in stage IV rhabdomyosarcoma , 2018, Pediatric blood & cancer.

[11]  K. McHugh,et al.  Open-label, multicentre, randomised, phase II study of the EpSSG and the ITCC evaluating the addition of bevacizumab to chemotherapy in childhood and adolescent patients with metastatic soft tissue sarcoma (the BERNIE study). , 2017, European journal of cancer.

[12]  G. Gatta,et al.  Access to clinical trials for adolescents with soft tissue sarcomas: Enrollment in European pediatric Soft tissue sarcoma Study Group (EpSSG) protocols , 2017, Pediatric blood & cancer.

[13]  James R. Anderson,et al.  Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  S. Abish,et al.  Radiotherapy is Important for Local Control at Primary and Metastatic Sites in Pediatric Rhabdomyosarcoma , 2015, Cureus.

[15]  S. Wolden,et al.  Radiation for bone metastases in Ewing sarcoma and rhabdomyosarcoma , 2015, Pediatric blood & cancer.

[16]  M. LaQuaglia,et al.  Favorable outcomes after whole abdominopelvic radiation therapy for pediatric and young adult sarcoma , 2014, Pediatric blood & cancer.

[17]  P. Rohrlich,et al.  Allogeneic stem cell transplantation for patients with advanced rhabdomyosarcoma: a retrospective assessment , 2013, British Journal of Cancer.

[18]  Andrea Ferrari,et al.  Soft tissue sarcoma across the age spectrum: A population‐based study from the surveillance epidemiology and end results database , 2011, Pediatric blood & cancer.

[19]  Arthur K Liu,et al.  Local control of metastatic sites with radiation therapy in metastatic Ewing sarcoma and rhabdomyosarcoma , 2011, Pediatric blood & cancer.

[20]  P. Winkler,et al.  Embryonal rhabdomyosarcoma with metastases confined to the lungs: Report from the CWS Study Group , 2011, Pediatric blood & cancer.

[21]  J. Merks,et al.  High-dose chemotherapy for children and young adults with stage IV rhabdomyosarcoma. , 2010, The Cochrane database of systematic reviews.

[22]  D. Machin,et al.  Outcomes in paediatric metastatic rhabdomyosarcoma: results of The International Society of Paediatric Oncology (SIOP) study MMT-98. , 2010, European journal of cancer.

[23]  A. Ferrari,et al.  Sequential high-dose chemotherapy for children with metastatic rhabdomyosarcoma. , 2009, European journal of cancer.

[24]  A. Ferrari,et al.  Adolescents with cancer in Italy: entry into the national cooperative paediatric oncology group AIEOP trials. , 2009, European journal of cancer.

[25]  James R. Anderson,et al.  Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  T. Klingebiel,et al.  Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: Report of the HD CWS‐96 trial , 2008, Pediatric blood & cancer.

[27]  H. V. Houwelingen.  Dynamic Prediction by Landmarking in Event History Analysis , 2007 .

[28]  M. Carli,et al.  European intergroup studies (MMT4-89 and MMT4-91) on childhood metastatic rhabdomyosarcoma: final results and analysis of prognostic factors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  A. Ferrari,et al.  Vinorelbine and low‐dose cyclophosphamide in the treatment of pediatric sarcomas , 2004, Cancer.

[30]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[31]  N. André,et al.  Does aggressive local treatment have an impact on survival in children with metastatic rhabdomyosarcoma? , 2015, European journal of cancer.

[32]  S. Donaldson,et al.  Characteristics and outcomes of rhabdomyosarcoma patients with isolated lung metastases from IRS-IV. , 2005, Journal of pediatric surgery.

[33]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[34]  D.,et al.  Regression Models and Life-Tables , 2022 .